- Home
- BFRI vs CANF Comparison
BFRI vs CANF Comparison
Compare BFRI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- CANF
- Stock Information
- Founded
- BFRI 1997
- CANF 1994
- Country
- BFRI United States
- CANF Israel
- Employees
- BFRI N/A
- CANF N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- BFRI Health Care
- CANF Health Care
- Exchange
- BFRI Nasdaq
- CANF Nasdaq
- Market Cap
- BFRI 10.6M
- CANF 9.6M
- IPO Year
- BFRI 2021
- CANF N/A
- Fundamental
- Price
- BFRI $1.03
- CANF $0.48
- Analyst Decision
- BFRI Strong Buy
- CANF Strong Buy
- Analyst Count
- BFRI 1
- CANF 2
- Target Price
- BFRI $2.75
- CANF $14.50
- AVG Volume (30 Days)
- BFRI 86.2K
- CANF 294.6K
- Earning Date
- BFRI 11-12-2025
- CANF 11-27-2025
- Dividend Yield
- BFRI N/A
- CANF N/A
- EPS Growth
- BFRI N/A
- CANF N/A
- EPS
- BFRI N/A
- CANF N/A
- Revenue
- BFRI $39,188,000.00
- CANF $560,000.00
- Revenue This Year
- BFRI $9.70
- CANF $461.72
- Revenue Next Year
- BFRI $12.58
- CANF N/A
- P/E Ratio
- BFRI N/A
- CANF N/A
- Revenue Growth
- BFRI 11.20
- CANF N/A
- 52 Week Low
- BFRI $0.54
- CANF $0.46
- 52 Week High
- BFRI $2.22
- CANF $2.55
- Technical
- Relative Strength Index (RSI)
- BFRI 53.39
- CANF 30.81
- Support Level
- BFRI $0.95
- CANF $0.46
- Resistance Level
- BFRI $1.15
- CANF $0.49
- Average True Range (ATR)
- BFRI 0.06
- CANF 0.03
- MACD
- BFRI 0.01
- CANF -0.00
- Stochastic Oscillator
- BFRI 50.00
- CANF 10.83
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).